Chardan Capital Maintains Buy on Dyne Therapeutics, Maintains $38 Price Target
Benzinga Newsdesk 7 months ago
NewsPrice TargetAnalyst Ratings
Chardan Capital analyst Keay Nakae maintains Dyne Therapeutics (NASDAQ:DYN) with a Buy and maintains $38 price target.
Chardan Capital analyst Keay Nakae maintains Dyne Therapeutics (NASDAQ:DYN) with a Buy and maintains $38 price target.